Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-22 02:02 UTC

BIOMED PULSE

July 22, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Ebola Bundibugyo virus outbreak in DRC and Uganda has now reached 2,124 confirmed cases and 828 deaths as of July 15 — the largest recorded BVD outbreak ever — with the PARTNERS clinical trial now enrolling patients in DRC to find the first effective treatments. The overall mood is urgent: multiple simultaneous outbreaks (Ebola, hantavirus, Cyclospora, West Nile) are straining global response capacity even as WHO releases landmark dementia prevention guidelines suggesting nearly half of cases are preventable. [1] [2] [3]

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS (DRC & UGANDA) — PHEIC ACTIVE

  • As of July 15, 2026, 2,124 confirmed cases and 828 deaths have been reported from DRC and Uganda, with sustained cross-border transmission ongoing. [2]
  • The WHO Director-General declared the BVD outbreak a Public Health Emergency of International Concern on May 22, 2026, though it does not yet meet the threshold for pandemic emergency. [4]
  • Africa CDC and WHO launched a joint continental Ebola response plan on June 5, 2026, seeking to raise US$518 million to support African countries in preparedness and response. [5]
  • WHO issued its first comprehensive clinical management guidelines for filovirus diseases, covering all Ebola types including Bundibugyo and Marburg, on June 17, 2026. [6]
  • WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing on July 2, 2026, enabling rapid confirmation from blood samples. [7]
  • The PARTNERS clinical trial opened patient enrolment in DRC on July 2, 2026, aiming to identify the first effective treatments specifically for Bundibugyo virus disease. [3]
  • CDC has activated enhanced Ebola airport screening at Washington-Dulles International Airport and Atlanta, with both airports now operational for traveler surveillance. [8] [9]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The Andes hantavirus (ANDV) outbreak linked to the M/V Hondius cruise ship, first reported to WHO on May 2, 2026, has produced multiple confirmed cases of severe acute respiratory illness across international passengers. [10]
  • As of the fifth WHO Disease Outbreak News report (July 2, 2026), additional confirmed cases have accumulated since the initial cluster of seven cases (two confirmed, five suspected) aboard a ship carrying 147 passengers and crew. [10]
  • CDC provided updated hantavirus response briefings on June 24, 2026, indicating ongoing monitoring; the agency has stated the risk to the general American public remains extremely low.

CYCLOSPORIASIS — TACO BELL, FIVE U.S. STATES

  • Shredded iceberg lettuce served at Taco Bell locations has been identified as the source of Cyclospora infections across five states, with 1,644 people reported sick as of July 17, 2026.
  • CDC held a Cyclosporiasis response briefing transcript on July 14, 2026; Cyclospora cayetanensis is a microscopic parasite spread through contaminated food or water.

WEST NILE VIRUS — EARLY U.S. SEASON

  • CDC reported an early West Nile virus season with record case counts as of July 1, 2026, urging Americans to use mosquito repellent, particularly over the Independence Day holiday weekend.

NIPAH VIRUS — INDIA (KERALA)

  • On June 11, 2026, Kerala State confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district in an adult male who developed neurological symptoms on May 30, 2026 and was hospitalized June 10.
  • A separate NiV case in Rajshahi Division, Bangladesh was reported to WHO on February 6, 2026, involving fever and neurological symptoms confirmed by laboratory testing.

MPOX — RECOMBINANT STRAIN, GLOBAL

  • WHO reported two cases globally of a recombinant monkeypox virus (MPXV) strain combining genomic elements of clades Ib and IIb, documented via known natural recombination processes when two strains co-infect one host.

AVIAN INFLUENZA A(H9N2) — ITALY

  • Italy notified WHO of a human A(H9N2) case on March 21, 2026 — an adult male returning from Senegal, with next-generation sequencing confirming the subtype; no sustained human-to-human transmission was reported.

YELLOW FEVER — GLOBAL

  • From January 1 to May 26, 2026, six countries reported a total of 79 human infections, with transmission activity continuing into 2026 following an elevated 2025 season in the Americas.

E. COLI — FROZEN BLUEBERRIES

  • CDC issued a food safety alert on July 7, 2026 warning against consuming recalled frozen blueberries linked to an E. coli outbreak; consumers are advised not to eat the recalled product.

MEASLES — BANGLADESH

  • As of April 23, 2026, WHO reported 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts in all eight divisions of Bangladesh, representing a nationwide surge.

🧬 LONGEVITY & AGING

WHO DEMENTIA PREVENTION GUIDELINES — UP TO 45% OF RISK MODIFIABLE

  • WHO released updated guidelines on July 15, 2026 concluding that up to 45% of dementia risk could be prevented or delayed through evidence-based interventions across the life course.
  • The guidelines provide countries with specific recommendations targeting modifiable risk factors including cardiovascular health, hearing loss, physical inactivity, depression, and social isolation.

DELIRIUM AS A BRIDGE BETWEEN INFECTION AND DEMENTIA

  • Two new papers in Lancet Healthy Longevity (items 277, 278) examine whether delirium during severe infection is the mechanistic missing link that accelerates subsequent dementia onset in older adults.
  • Authors Sipilä and Kivimäki argue that infection-induced neuroinflammation causing delirium may leave lasting brain damage detectable years later as dementia, calling for prospective study.

NAD+ RESTORATION FOR AGED BONE REPAIR

  • A study published in Bioactive Materials (June 27, 2026) tested a hierarchical scaffold designed to restore NAD+ homeostasis and redox balance in senescent cells, demonstrating improved bone repair in aged tissue models.
  • The mechanism involves targeting senescent metabolism: NAD+ depletion is a hallmark of cellular aging that impairs tissue regeneration, and restoring it via the scaffold reversed several senescent phenotypes.

KAEMPFEROL FROM MORINGA AND LONGEVITY IN DROSOPHILA

  • A study published June 25, 2026 in Toxicology Reports found that kaempferol extracted from Moringa oleifera increased lifespan and reduced efavirenz-induced functional senescence markers in Drosophila melanogaster.
  • Authors Iorjiim et al. propose kaempferol's antioxidant and anti-senescence properties as the mechanism, though translation to human aging biology requires further study.

EMERIN, TAU, AND NEURONAL CYTOSKELETAL REMODELING

  • A July 7, 2026 study in Nucleus found that the nuclear envelope protein emerin, mechanically sensitive, is elevated in neurons in tau pathology models, linking nuclear mechanotransduction to tau-driven cytoskeletal changes relevant to Alzheimer's disease.

COLLAGEN XVII AND SKIN STEM CELL PHOTOAGING

  • Research published July 16, 2026 in Annals of Medicine showed recombinant human collagen XVII protects epidermal stem cells from blue light-induced photoaging by downregulating the Notch signaling pathway.
  • This mechanism is significant for skin longevity because epidermal stem cell exhaustion is a core hallmark of skin aging.

HYPERTENSION-FRAILTY LINK IN OLDER ADULTS

  • A letter to the editor in Blood Pressure (July 7, 2026) responded to data from the Longitudinal Ageing Study in India documenting associations between hypertension and frailty in middle-aged and older adults, underscoring cardiovascular control as a frailty prevention target.

DEMENTIA PREVENTION IN THE REAL WORLD

  • A commentary in Lancet Healthy Longevity (item 276) by Beeri and Gu calls for dementia prevention strategies designed for diverse, real-world populations — not just those enrolled in idealized clinical trials — as the prevention era approaches.

💊 NEW CURES & APPROVALS

ENLICITIDE (ENLICITIDE CHLORIDE) — MERCK SHARP AND DOHME LLC

  • Merck's ENLICITIDE (enlicitide chloride, NDA220848) received an original FDA approval action, representing a new molecular entity from the openFDA Drugs@FDA database.

REVTORPYK (GEDATOLISIB) — CELCUITY INC.

  • Celcuity's REVTORPYK (gedatolisib, NDA219908) received an original FDA approval action; gedatolisib is a dual PI3K/mTOR inhibitor with potential relevance to cancer indications where the PI3K pathway is dysregulated.

REPATHA (EVOLOCUMAB) SUPPLEMENTAL — AMGEN INC.

  • Amgen's Repatha (evolocumab, BLA125522) received a supplemental FDA approval action; evolocumab is a PCSK9 inhibitor used for LDL-cholesterol lowering and cardiovascular risk reduction.

RETEVMO (SELPERCATINIB) SUPPLEMENTAL — ELI LILLY AND CO.

  • Eli Lilly's Retevmo (selpercatinib, NDA213246 and NDA218160) received supplemental FDA approval actions; selpercatinib is a RET kinase inhibitor approved for RET-altered cancers including thyroid and lung cancers.

AFATINIB DIMALEATE GENERICS — HETERO LABS / APOTEX

  • Generic afatinib dimaleate original approval actions were recorded for Hetero Labs (ANDA210750) and Apotex (ANDA210725), expanding access to this EGFR/HER2 inhibitor used in non-small-cell lung cancer.

🧪 CLINICAL TRIALS

SENSORY INTEGRATION TRAINING FOR FALL PREVENTION IN OLDER ADULTS

  • A trial registered July 21, 2026 (NCT07717034) is evaluating sensory integration training targeting visual, vestibular, and somatosensory decline in adults aged 60 and older to improve static standing balance and reduce fall risk.

DIMETHYL FUMARATE FOR TYPE 1 DIABETES BETA-CELL PRESERVATION

  • An open-label, parallel-controlled single-center trial (NCT07548996, registered July 21, 2026) is testing dimethyl fumarate's efficacy in preserving pancreatic beta-cell function in adults with type 1 diabetes, assessing both efficacy and tolerability.

ZONGERTINIB (BEAMION PANTUMOR-1) FOR HER2-ALTERED ADVANCED CANCERS

  • A study (NCT06581432) is testing zongertinib in adults aged 18 and over with advanced cancers bearing HER2 alterations who have failed prior treatment — a basket trial design relevant to multiple aging-associated cancers.

MIRDAMETINIB PLUS SIROLIMUS FOR RAS-MUTATED RELAPSED/REFRACTORY MULTIPLE MYELOMA

  • Trial NCT06876142 (registered July 21, 2026) is evaluating combination MEK inhibition (mirdametinib) plus mTOR inhibition (sirolimus) in relapsed/refractory multiple myeloma patients with KRAS or NRAS mutations.

IMATINIB FOR GERMLINE RUNX1 DEFICIENCY

  • Trial NCT06090669 is testing imatinib to increase RUNX1 transcription factor activity in patients with germline RUNX1 mutations, who face elevated risk of blood cancers and bleeding disorders.

MOSAIC HEXAVALENT INFLUENZA VACCINE FLIMOS-V2 WITH ALFQ ADJUVANT

  • Trial NCT06863142 (registered July 21, 2026) is evaluating dose, safety, tolerability, and immunogenicity of the experimental broad-spectrum FluMos-v2 influenza vaccine with and without the ALFQ adjuvant in healthy adults.

N-ACETYL-D-MANNOSAMINE (MANNAC) FOR FOCAL SEGMENTAL GLOMERULOSCLEROSIS

  • An open-label Phase 2 trial (NCT06664814, registered July 21, 2026) is testing ManNAc in patients with primary FSGS, a kidney scarring disease that can progress to dialysis or transplant; the sialic acid precursor aims to reduce proteinuria.

📢 PUBLIC HEALTH

WHO DEMENTIA GUIDELINES HEADLINE PREVENTION AGENDA

  • WHO's July 15, 2026 dementia risk-reduction guidelines are the most comprehensive update to date, applicable across the full life course and targeting both individual and structural determinants of brain aging.

WHO CANCER PROJECTION — CASES TO NEARLY DOUBLE BY 2050

  • WHO reported July 8, 2026 that new cancer cases are projected to reach roughly 40 million annually by 2050 (up from 20.6 million currently), with cancer already claiming over 26,000 lives per day globally.

GLOBAL CHILDHOOD IMMUNIZATION — 90% DTP FIRST DOSE IN 2025

  • WHO-UNICEF data released July 15, 2026 show 90% of infants globally (approximately 116 million) received at least one DTP vaccine dose in 2025, with 85% completing the full three-dose series.

CDC HEALTHCARE-ASSOCIATED INFECTIONS DECLINE

  • CDC data released July 15, 2026 show a decline in hospital-acquired infections in 2023, reflecting improved patient safety practices across U.S. healthcare facilities.

CDC TRAVELER GENOMIC SURVEILLANCE SURPASSES 1 MILLION PARTICIPANTS

  • CDC's Traveler-Based Genomic Surveillance program, which screens international air travelers for novel pathogens, surpassed one million voluntary participants as of January 30, 2026.

EL SALVADOR ELIMINATES TRACHOMA

  • WHO validated El Salvador as having eliminated trachoma as a public health problem on July 13, 2026; trachoma is the world's leading infectious cause of preventable blindness.

DRUG-RESISTANT BACTERIA — SHARP RISE FLAGGED BY CDC

  • A CDC report released September 23, 2025 documented a dramatic increase in dangerous drug-resistant bacteria, underscoring the ongoing antimicrobial resistance threat to hospitalized patients.

This briefing is informational only and does not constitute medical advice. Always consult a qualified healthcare provider for clinical decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  3. Patient enrolment begins in a scientific trial to identify the… — WHO News
  4. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  5. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  6. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  7. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  8. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  9. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260722-02-v35 · 2026-07-22 02:02 UTC · pulse.uzylab.com

Read next